+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of acute leukemia with topotecan-based chemotherapy



Treatment of acute leukemia with topotecan-based chemotherapy



Blood 94(10 SUPPL 1 PART 1): 291a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035980777

Download citation: RISBibTeXText


Related references

A new combination chemotherapy using topotecan, fludarabine, Ara-C and G-CSF for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly Dose finding for topotecan study. Blood 94(10 SUPPL 1 PART 1): 307a, Nov 15, 1999

Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. Leukemia & Lymphoma 43(5): 989-999, 2002

Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15(6): 963-970, 2001

Topotecan and idarubicin as chemotherapy in relapsed acute myeloid leukemia Preliminary results on eight patients. Onkologie 23(Sonderheft 7): 28, October, 2000

Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia. Hematology/Oncology and Stem Cell Therapy 3(4): 199-202, 2012

Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia. Leukemia & Lymphoma 56(10): 2962-2964, 2016

Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome. Korean Journal of Internal Medicine 15(2): 122-126, 2000

Topotecan, fludarabine, Ara-C and G-CSF for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly A dose finding for topotecan study. Blood 96(11 Part 2): 259b, November 16, 2000

Comparison of the cyclophosphamide , ara-C , topotecan , regimen to ara-C plus topotecan or idarubicin as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia. Blood 94(10 SUPPL 1 PART 2): 226b, Nov 15, 1999

Phase II study of timed sequential chemotherapy with Topotecan followed by Mitoxantrone + Etoposide in the treatment of refractory leukemia and lymphoma. Blood 94(10 SUPPL 1 PART 1): 509a, Nov 15, 1999

New developments in the treatment of acute myeloid leukemia: focus on topotecan. Seminars in Hematology 36(4 Suppl 8): 16-25, 2000

New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids. Leukemia 12 Suppl 1: S13-S15, 1998

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy. International Journal of General Medicine 8: 211-214, 2015

Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia. Blood 96(11 Part 2): 209b, November 16, 2000

The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia. Haematologica 86(4): 440-441, 2001